The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Postdoctoral Researcher in Breast Cancer Translational Research”
Reference: Ref. 06-2021
Application deadline: April 21, 2021
Number of vacancies: 1
Job description:
A postdoctoral position is available immediately at the Experimental Therapeutics Group at the Vall d’Hebron Institute of Oncology (PI: Violeta Serra), Barcelona, Spain. We look for a highly-motivated postdoctoral scientist to develop an independent research line on liquid biopsy, centered towards the development of an assay to detect DNA repair biomarkers in circulating tumor cells. The main tasks will include, among others:
- Management and analysis of blood samples form patients treated at our Hospital
- Implementation of circulating tumor cells (CTCs) enrichment protocols
- Development of DNA repair functionality assays in CTCs
- Analysis of circulating tumor DNA (ctDNA)
Our group has a long tradition in studying and testing hypothesis-based targeted therapy in breast cancer. Our research is committed to the clinical implications of our findings in relation to ongoing and future clinical trials. In this sense, we closely collaborate with Dr. Cristina Saura, Dr. Judith Balmaña and Dr. Joaquin Mateo from the Breast Cancer, Genetic Counseling and Prostate Cancer Units at the Vall d’Hebron University Hospital. The candidate will be involved in the implementation of a biomarker for PARP inhibitors. Specifically, we developed an immune-based assay to quantify the functionality of DNA repair by homologous recombination and we are currently performing the clinical validation of the assay. The duration of the position is 2 years, with possibility to extend to 3.
Requirements:
We are looking for a postdoctoral candidate (PhD) with background in cancer biology and previous experience isolating and analyzing CTCs.
Candidacy for EU-funded fellowship programs will be preferred.
Fluency in English is mandatory.
Application:
Please email a motivation letter with scientific interests, CV, and 2-3 reference letters to: selecciorrhh@vhio.net. Please use “Ref. 06-2021 Postdoc ETG” as the subject line in your email.
About VHIO:
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.
